Kinnate Biopharma, Inc. (KNTE)
| Market Cap | 439.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -99.21M |
| Shares Out | 43.98M |
| EPS (ttm) | -2.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,834 |
| Open | 10.05 |
| Previous Close | 10.43 |
| Day's Range | 9.99 - 10.38 |
| 52-Week Range | 7.29 - 26.05 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 42.33 (+323.9%) |
| Earnings Date | May 16, 2022 |
About KNTE
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dep...
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is 42.33, which is an increase of 323.94% from the latest price.
News
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its FGFR Inhibitor Product Candidat...
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ...
Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Stud...
Three poster presentations highlight the unmet need for targeted therapies in BRAF and/or NRAS-altered cancers, including non-small cell lung cancer and melanoma Three poster presentations highlight the...
Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates
Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022
Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Rese...
Poster presentations to highlight data from ongoing studies of the company's lead Pan-RAF kinase inhibitor program, KIN-2787 Poster presentations to highlight data from ongoing studies of the company's ...
Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtu...
Findings highlight the unmet medical need among cancer patients with BRAF Class II and Class III alterations who may not have access to approved targeted therapies
Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IA...
Presentation to focus on antitumor activity of KIN-2787 in preclinical models of human BRAF-alteration driven non-small cell lung cancer Presentation to focus on antitumor activity of KIN-2787 in precli...
Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cance...
Presentation to highlight data from preclinical studies of the company's next-generation pan-FGFR inhibitor, KIN-3248, and its activity against acquired FGFR gatekeeper and molecular brake drug-resistan...
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022 Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022
Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones
Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma
Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scienti...
AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutati...
Kinnate Biopharma Inc. Announces Addition to NASDAQ Biotechnology Index
SAN FRANCISCO and SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results
In collaboration with Guardant Health, announced initial findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study
Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer
Dr. Eric Murphy to serve on the company's Scientific Advisory Board Dr. Eric Murphy to serve on the company's Scientific Advisory Board
Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtua...
The KN-8701 trial is a multi-center, open-label, two-part trial of Kinnate's lead RAF inhibitor candidate KIN-2787 The KN-8701 trial is a multi-center, open-label, two-part trial of Kinnate's lead RAF i...
Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results
Announced first patient dosed in Phase 1 trial evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors
Should You Buy Kinnate Biopharma (KNTE) Ahead of Earnings?
Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021
SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors
Accomplished immunologist and veteran biopharma executive has extensive experience in advancing pre-clinical stage oncology programs into the clinic Accomplished immunologist and veteran biopharma execu...
Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expa...
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021
Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations Data highlights in vitro and in vivo activity of KIN-2787 against...
Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ki...
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
SAN FRANCISCO and SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ki...
Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting
SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)---- $KNTE #ASCO--Data highlights pre-clinical activity of KIN-2787 in Class II and Class III BRAF-mutant models